Company profile
Cellectis S.A.
NASDAQ:CLLSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Lasmecabtagene Timgedleucel | phase1_2 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04150497 | phase1_2 | recruiting | 2019-10-14 | 2026-06-30 | Cellectis S.A. | Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) |
| NCT04106076 | phase1 | withdrawn | 2019-07-11 | 2019-12-05 | Cellectis S.A. | Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia |
| NCT04142619 | phase1 | terminated | 2019-11-21 | 2023-06-18 | Cellectis S.A. | Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) |
| NCT03190278 | phase1 | active_not_recruiting | 2017-06-19 | 2024-12-24 | Cellectis S.A. | Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
| NCT05607420 | phase1_2 | recruiting | 2022-11-01 | 2027-08-01 | Cellectis S.A. | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma |
FDA applications (0)
No records yet.